
Insider and congress filings
Labcorp Holdings Inc. (LH)
NYSE · Healthcare · 313 insider transactions · 81 congress trades · last filed 2 months agoS&P 500
About Labcorp Holdings Inc.
from the company's filings and listing, as of Oct 22, 2026- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Chief executive
- Adam H. Schechter
- Employees
- 71,000
- Listed since
- Mar 29, 1990
- Market value
- $26.3B
- Price to earnings (12 mo)
- 26.6
- Net income per share, as reported (12 mo)
- $12.27
- Dividend yield
- 0.89%
Earnings
6 reported quarters · next on Oct 28, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 30, 2026 | $4.99 | $4.78 | $3.7B | $3.7B | EPS beatRevenue in line |
| Q1 FY2026reported Apr 30, 2026 | $4.25 | $4.11 | $3.5B | $3.5B | EPS beatRevenue in line |
| Q4 FY2025reported Feb 17, 2026 | $4.07 | $3.95 | $3.5B | $3.6B | EPS beatRevenue in line |
| Q3 FY2025reported Oct 28, 2025 | $4.18 | $4.13 | $3.6B | $3.6B | EPS in lineRevenue in line |
| Q2 FY2025reported Jul 24, 2025 | $4.35 | $4.17 | $3.5B | $3.5B | EPS beatRevenue in line |
| Q1 FY2025reported Apr 29, 2025 | $3.84 | $3.74 | $3.3B | $3.4B | EPS beatRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 10, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Adam H. SchechterPresident and Chief Executive Officer | $1.4M | $11.4M | $5.5M | $18.3M |
| Julia A. WangExecutive Vice President and Chief Financial Officer | $738K | $2.7M | $1.6M | $5.0M |
| Brian J. CaveneyExecutive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer | $748K | $2.3M | $1.3M | $4.4M |
| Megan D. BaileyExecutive Vice President and President, Central Laboratories and International | $569K | $1.3M | $890K | $2.7M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $1.8B | 6,574,261 | +2.0% | 8.05% |
| Vanguard Capital Management LLC | $1.5B | 5,362,254 | -0.3% | 6.56% |
| Victory Capital Management Inc | $1.4B | 4,837,573 | +4.5% | 5.92% |
| State Street Corp | $1.1B | 3,907,656 | +1.2% | 4.75% |
| Vanguard Portfolio Management LLC | $1.0B | 3,678,798 | -0.1% | 4.50% |
| Boston Partners | $854.2M | 3,051,690 | +28.8% | 3.74% |
| Allspring Global Investments Holdings, LLC | $635.0M | 2,236,957 | +0.5% | 2.74% |
| Geode Capital Management, LLC | $610.4M | 2,188,890 | +0.1% | 2.68% |
| Select Equity Group, L.P. | $554.9M | 1,981,948 | -8.9% | 2.43% |
| FMR LLC | $533.4M | 1,904,870 | +47.8% | 2.33% |
| Morgan Stanley | $450.6M | 1,609,447 | +7.4% | 1.97% |
| Dimensional Fund Advisors LP | $382.8M | 1,367,166 | +2.6% | 1.67% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Open-market insider trades
16 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Kerrii B. AndersonDirector | Sold · scheduled | 3,000 | $318.02 | $954K | Aug 17, 2026filed Aug 18, 2026 | 1d |
| Adam H. SchechterPresident & CEO | Sold · scheduled | 4,669 | $320.37 | $1.5M | Aug 11, 2026filed Aug 12, 2026 | 1d |
| Amy B. SummyEVP, Chief Marketing Officer | Sold | 924 | $306.74 | $283K | Aug 4, 2026filed Aug 6, 2026 | 2d |
| Peter J. WilkinsonSVP, Chief Accounting Officer | Sold · 2 lines | 1,420 | $309.23 | $439K | Aug 3, 2026filed Aug 5, 2026 | 2d |
| Bryan T. VaughnEVP and President, Diagnostics | Sold · scheduled | 234 | $286.19 | $67K | Jul 2, 2026filed Jul 6, 2026 | 1d |
| Kathryn W. KyleEVP, Chief Legal Officer | Sold · scheduled | 92 | $286.19 | $26K | Jul 2, 2026filed Jul 6, 2026 | 1d |
| Kathryn W. KyleEVP, Chief Legal Officer | Sold · scheduled | 762 | $263.89 | $201K | Jun 8, 2026filed Jun 10, 2026 | 2d |
| Adam H. SchechterPresident & CEO | Sold · scheduled | 5,903 | $254.50 | $1.5M | May 11, 2026filed May 13, 2026 | 2d |
| Jonathan C. MeltzerEVP, Operations | Sold · scheduled | 839 | $267.05 | $224K | Mar 27, 2026filed Mar 30, 2026 | 1d |
| Peter J. WilkinsonSVP, Chief Accounting Officer | Sold · scheduled | 1,633 | $267.05 | $436K | Mar 27, 2026filed Mar 30, 2026 | 1d |
| Adam H. SchechterPresident & CEO | Sold | 8,705 | $279.96 | $2.4M | Mar 3, 2026filed Mar 5, 2026 | 2d |
| Sandra D. van der VaartEVP, Corporate Affairs | Sold | 548 | $284.91 | $156K | Feb 27, 2026filed Mar 3, 2026 | 2d |
| Brian J. CaveneyEVP, Pres of ED, CMO & CSO | Sold | 1,500 | $286.31 | $429K | Feb 24, 2026filed Feb 26, 2026 | 2d |
| Peter J. WilkinsonSVP, Chief Accounting Officer | Sold · scheduled | 666 | $277.94 | $185K | Feb 19, 2026filed Feb 23, 2026 | 2d |
| Jonathan C. MeltzerEVP, Operations | Sold · scheduled | 87 | $290.42 | $25K | Feb 12, 2026filed Feb 13, 2026 | 1d |
| Adam H. SchechterPresident & CEO | Sold · scheduled | 5,273 | $284.38 | $1.5M | Feb 11, 2026filed Feb 13, 2026 | 2d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Brian J. CaveneyEVP, Pres of BLS, CMO & CSO | Stock award | 3,000 | Sep 1, 2026 |
| Bryan T. VaughnEVP and President, Diagnostics | Stock award | 1,500 | Sep 1, 2026 |
| Jonathan C. MeltzerEVP, COO | Stock award | 900 | Sep 1, 2026 |
| Akinbolade OyegunwaEVP, CIO & CTO | Stock award | 750 | Sep 1, 2026 |
| Peter J. WilkinsonSVP, Chief Accounting Officer | Option exercise | 1,338 | Aug 3, 2026 |
| Bryan T. VaughnEVP and President, Diagnostics | Tax withholding | 93 | Jul 1, 2026 |
| Bryan T. VaughnEVP and President, Diagnostics | Option exercise | 327 | Jul 1, 2026 |
| Kathryn W. KyleEVP, Chief Legal Officer | Tax withholding | 73 | Jul 1, 2026 |
| Kathryn W. KyleEVP, Chief Legal Officer | Option exercise | 256 | Jul 1, 2026 |
| Megan D. BaileyEVP, Pres, Central Labs & Intl | Tax withholding | 481 | Mar 26, 2026 |
| Megan D. BaileyEVP, Pres, Central Labs & Intl | Stock award | 1,184 | Mar 26, 2026 |
| Kathryn W. KyleEVP, Chief Legal Officer | Tax withholding | 451 | Mar 26, 2026 |
| Kathryn W. KyleEVP, Chief Legal Officer | Stock award | 1,584 | Mar 26, 2026 |
| Jonathan C. MeltzerEVP, Operations | Tax withholding | 711 | Mar 26, 2026 |
| Jonathan C. MeltzerEVP, Operations | Stock award | 2,388 | Mar 26, 2026 |
| Akinbolade OyegunwaEVP, CIO & CTO | Tax withholding | 382 | Mar 26, 2026 |
| Akinbolade OyegunwaEVP, CIO & CTO | Stock award | 1,340 | Mar 26, 2026 |
| Amy B. SummyEVP, Chief Marketing Officer | Tax withholding | 1,836 | Mar 26, 2026 |
| Amy B. SummyEVP, Chief Marketing Officer | Stock award | 3,994 | Mar 26, 2026 |
| Sandra D. van der VaartEVP, Corporate Affairs | Tax withholding | 2,722 | Mar 26, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress trades in LH
20 disclosures of 81 on record · median 16d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| April McClain DelaneyDependent child | Stock | Sale | $100,001 - $250,000 | -2.6%After the saleS&P 500 -0.8% · -1.8 pts vs S&P 500 | Aug 25, 2026 | Sep 9, 2026 | 15d |
| April McClain DelaneyDependent child | Stock | Sale | $1,001 - $15,000 | +4.8%After the saleS&P 500 -1.3% · +6.1 pts vs S&P 500 | Aug 5, 2026 | Sep 9, 2026 | 35d |
| April McClain DelaneyDependent child | Stock | Sale | $1,001 - $15,000 | +3.9%After the saleS&P 500 -1.1% · +5.0 pts vs S&P 500 | Aug 6, 2026 | Sep 9, 2026 | 34d |
| April McClain DelaneyDependent child | Stock | Sale | $1,001 - $15,000 | +3.1%After the saleS&P 500 -1.7% · +4.8 pts vs S&P 500 | Aug 7, 2026 | Sep 9, 2026 | 33d |
| Alan ArmstrongSelf | Stock | Purchase | $1,001 - $15,000 | +24.5%S&P 500 +19.8% · +4.7 pts vs S&P 500 | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +17.5%After the saleS&P 500 +1.7% · +15.8 pts vs S&P 500 | Jun 30, 2026 | Jul 6, 2026 | 6d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +31.4%S&P 500 +2.8% · +28.6 pts vs S&P 500 | May 15, 2026 | Jun 9, 2026 | 25d |
| April McClain DelaneyDependent child | Stock | Purchase | $1,001 - $15,000 | +19.1%S&P 500 +10.7% · +8.4 pts vs S&P 500 | Feb 4, 2026 | Mar 10, 2026 | 34d |
| April McClain DelaneyDependent child | Stock | Purchase | $1,001 - $15,000 | +13.5%S&P 500 +9.8% · +3.7 pts vs S&P 500 | Feb 11, 2026 | Mar 10, 2026 | 27d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +31.4%After the saleS&P 500 +9.3% · +22.1 pts vs S&P 500 | Jan 12, 2026 | Feb 6, 2026 | 25d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +21.9%After the saleS&P 500 +9.5% · +12.5 pts vs S&P 500 | Jan 29, 2026 | Feb 6, 2026 | 8d |
| April McClain DelaneyDependent child | Stock | Purchase | $1,001 - $15,000 | +22.7%S&P 500 +9.2% · +13.5 pts vs S&P 500 | Jan 28, 2026 | Feb 2, 2026 | 5d |
| April McClain DelaneyDependent child | Stock | Purchase | $1,001 - $15,000 | +25.9%S&P 500 +14.1% · +11.7 pts vs S&P 500 | Nov 17, 2025 | Dec 8, 2025 | 21d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +19.3%After the saleS&P 500 +10.9% · +8.5 pts vs S&P 500 | Oct 27, 2025 | Nov 6, 2025 | 10d |
| April McClain DelaneyDependent child | Stock | Purchase | $1,001 - $15,000 | +32.6%S&P 500 +10.5% · +22.0 pts vs S&P 500 | Oct 29, 2025 | Nov 4, 2025 | 6d |
| April McClain DelaneyDependent child | Stock | Purchase | $1,001 - $15,000 | +29.5%S&P 500 +11.4% · +18.1 pts vs S&P 500 | Oct 31, 2025 | Nov 4, 2025 | 4d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +26.0%After the saleS&P 500 +26.2% · -0.2 pts vs S&P 500 | Jun 23, 2025 | Jul 9, 2025 | 16d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +26.2%After the saleS&P 500 +23.2% · +3.0 pts vs S&P 500 | Jun 27, 2025 | Jul 9, 2025 | 12d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +33.2%S&P 500 +29.3% · +3.9 pts vs S&P 500 | May 28, 2025 | Jun 10, 2025 | 13d |
| Robert Bresnahan | Stock | Purchase | $1,001 - $15,000 | +33.6%S&P 500 +28.7% · +4.9 pts vs S&P 500 | May 15, 2025 | May 31, 2025 | 16d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in LH, filterable by party, chamber, type and account.
Members of Congress reporting a position
3 members · estimate, as of Oct 21, 20263 members report a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| J. French Hill | Republican · House | $50,001 - $100,000 | 0.6% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $1,001 - $15,000 | <0.1% |
| Robert Bresnahan | Republican · House | $1,001 - $15,000 | 0.1% |
Estimate, as of Oct 21, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Are insiders buying or selling LH?
Across the 16 most recent open-market filings shown here, 0 were purchases and 16 were sales. 11 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded LH?
April McClain Delaney, Alan Armstrong, Ro Khanna and Robert Bresnahan disclosed LH transactions in the filings shown here.
Which members of Congress hold LH?
3 members of Congress report a position in LH in the estimate we hold as of Oct 21, 2026. The estimated positions belong to J. French Hill, Gilbert Ray Cisneros, Jr. and Robert Bresnahan. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is LH in the S&P 500 or the Nasdaq 100?
Labcorp Holdings Inc. is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.
How quickly are LH trades disclosed?
Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 16 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.
